Lucas Mendicino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lucas Mendicino has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Angela R. Omilian
Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York
3 shared publications - Anselm J.M. Hennis
Department of Noncommunicable Diseases and Mental Health, Pan American Health Organization, Washington, District of Columbia
3 shared publications - Bingshan Li
Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA
3 shared publications - Chi-Chen Hong
Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York
3 shared publications - Christine B. Ambrosone
Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, USA
3 shared publications - Christopher A. Haiman
Department of Preventive Medicine, Keck School of Medicine of USC, Los Angeles, USA
3 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from The African-Specific Variant in the Duffy Antigen Receptor for Chemokines Gene, CD8+ T-Cell Density, and Aggressive Breast Cancer Subtypes in Black Women
Supplemental Figure S1. Log-transformed CD8+ T-cell density per mm2 by ACKR1/DARC genotype. Figure displays box plot distribution of CD8+ T-cell density per mm2 according to ACKR1/DARC genotype (N=428).
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The African-Specific Variant in the Duffy Antigen Receptor for Chemokines Gene, CD8+ T-Cell Density, and Aggressive Breast Cancer Subtypes in Black Women
Supplemental Figure S1. Log-transformed CD8+ T-cell density per mm2 by ACKR1/DARC genotype. Figure displays box plot distribution of CD8+ T-cell density per mm2 according to ACKR1/DARC genotype (N=428).
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from The African-Specific Variant in the Duffy Antigen Receptor for Chemokines Gene, CD8+ T-Cell Density, and Aggressive Breast Cancer Subtypes in Black Women
Supplemental Figure S2. Meta-analysis full forest plots from AABCG for rs2814778 in relation to risk of breast cancer overall, ER- and TNBC. Figure shows non-significant odds ratio (OR) estimates for breast cancer risk overall, ER- and TNBC for ACKR1/DARC variant, rs2814778 in reference to controls.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from The African-Specific Variant in the Duffy Antigen Receptor for Chemokines Gene, CD8+ T-Cell Density, and Aggressive Breast Cancer Subtypes in Black Women
Supplemental Figure S2. Meta-analysis full forest plots from AABCG for rs2814778 in relation to risk of breast cancer overall, ER- and TNBC. Figure shows non-significant odds ratio (OR) estimates for breast cancer risk overall, ER- and TNBC for ACKR1/DARC variant, rs2814778 in reference to controls.
- 8 July 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (9) , 1509-1515
The African-Specific Variant in the Duffy Antigen Receptor for Chemokines Gene, CD8+ T-Cell Density, and Aggressive Breast Cancer Subtypes in Black Women
Background: Immune response in blood varies by ancestry, linked to an African-specific variant (rs2814778) in the Duffy Antigen Receptor for Chemokines (DARC/ACKR1) gene. We examined associations between rs2814778, CD8+ T-cell density in breast tumors, and breast cancer risk in African-American/Black women. Methods: CD8+ T-cell density in tumors from 428 Black women were examined in relation to the rs2814778 variant. In the African Ancestry Breast Cancer Genetics (AABCG) Consortium with 16,886 cases and 18,044 controls, rs2814778 was evaluated in relation to risk of overall breast cancer and to more aggressive subtypes [estrogen receptor-negative (ER−) and triple-negative breast cancer (TNBC)]. Results: Women with the African-specific CC genotype had lower tumor CD8+ T-cell density (87.0 per mm2) than those with TT genotypes (146.6 per mm2; P < 0.05). Each T allele was significantly associated with an increase in T-cell density (P = 0.04). In the largest analysis, to date, there were no associations between rs2814778 and risk of overall breast cancer [OR = 0.90 (95% confidence interval (CI), 0.66–1.22)] or with ER− breast cancer [OR = 0.86 (95% CI, 0.68–1.08)] or TNBC [OR = 0.77 (95% CI, 0.56–1.05)]. Conclusions: Although breast tumors from women with the African-specific DARCC allele had lower CD8+ T-cell density levels than those with T alleles, in a large breast cancer consortium with adequate statistical power, the variant was not associated with breast cancer risk overall, nor with risk of ER− breast cancer or TNBC, as previously hypothesized. Impact: Although the “Duffy-null” allele has been the focus of research as a contributor to aggressive breast cancer in Black women, this study with 34,930 cases and controls found no associations with risk.
- 8 July 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (9) , 1509-1515
The African-Specific Variant in the Duffy Antigen Receptor for Chemokines Gene, CD8+ T-Cell Density, and Aggressive Breast Cancer Subtypes in Black Women
Background: Immune response in blood varies by ancestry, linked to an African-specific variant (rs2814778) in the Duffy Antigen Receptor for Chemokines (DARC/ACKR1) gene. We examined associations between rs2814778, CD8+ T-cell density in breast tumors, and breast cancer risk in African-American/Black women. Methods: CD8+ T-cell density in tumors from 428 Black women were examined in relation to the rs2814778 variant. In the African Ancestry Breast Cancer Genetics (AABCG) Consortium with 16,886 cases and 18,044 controls, rs2814778 was evaluated in relation to risk of overall breast cancer and to more aggressive subtypes [estrogen receptor-negative (ER−) and triple-negative breast cancer (TNBC)]. Results: Women with the African-specific CC genotype had lower tumor CD8+ T-cell density (87.0 per mm2) than those with TT genotypes (146.6 per mm2; P < 0.05). Each T allele was significantly associated with an increase in T-cell density (P = 0.04). In the largest analysis, to date, there were no associations between rs2814778 and risk of overall breast cancer [OR = 0.90 (95% confidence interval (CI), 0.66–1.22)] or with ER− breast cancer [OR = 0.86 (95% CI, 0.68–1.08)] or TNBC [OR = 0.77 (95% CI, 0.56–1.05)]. Conclusions: Although breast tumors from women with the African-specific DARCC allele had lower CD8+ T-cell density levels than those with T alleles, in a large breast cancer consortium with adequate statistical power, the variant was not associated with breast cancer risk overall, nor with risk of ER− breast cancer or TNBC, as previously hypothesized. Impact: Although the “Duffy-null” allele has been the focus of research as a contributor to aggressive breast cancer in Black women, this study with 34,930 cases and controls found no associations with risk.